To know the effectiveness and safety of Betahistine in patients with Vertigo
- Conditions
- Health Condition 1: null- Acute Peripheral VertigoHealth Condition 2: H813- Other peripheral vertigo
- Registration Number
- CTRI/2018/07/014797
- Lead Sponsor
- Dr Carlton Pereira
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Male or female aged >=18 years
2.Patients with confirmed peripheral vertigo based on clinical diagnosis
3.Patients naïve to treatment for peripheral vertigo
1.Patients with middle or inner ear infection, who required surgery
2.Patients suffering from brain tumor, head trauma, epilepsy, multiple sclerosis and paralysis of eye muscles
3.Patient with established psychiatric disorders, significant neurological disorder like Parkinsonâ??s disease or spinal cord damage.
4.Pregnant and lactating women
5.Patients with peptic ulcer
6.Patients with pheochromocytoma
7.Patients with bronchial asthma
8.Patients receiving any other agents for peripheral vertigo such as diuretics, transtympanic gentamycin, cinnarizine, and H1 antagonists (dimenhydrinate, promethazine, diphenhydramine etc.)
9.Patients who are regular users of excessive amount of drugs and alcohol
10.Patients with known hypersensitivity/allergic reaction to Betahistine
11.Participants in any clinical trial in past 30 days before enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To establish the efficacy of betahistine in treatment naïve acute peripheral vertigo patientsTimepoint: During Treatment period/Study duration.
- Secondary Outcome Measures
Name Time Method 1 To evaluate the effect of betahistine on frequency and severity of peripheral vertigo using VNG test. <br/ ><br>2 To evaluate the effect of betahistine on severity of peripheral vertigo using DHI and SVVSLCRE scales. <br/ ><br>Timepoint: During the study duration/treatment period.